Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wp-cerber domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/htdocs/w00e14a1/CPC-NEU2021/wp-includes/functions.php on line 6114
Indonesia: A lucrative market - Chameleon Pharma Consulting
+49 30 648 35 164 service@chameleon-pharma.com

Indonesia: A lucrative market

Ago, 16, 2013

Indone­sia has a decent-sized and fast-growing OTC, Med­ical Device and Pharma mar­ket that had an esti­mated value of approx­i­mately US $6.25 billion in 2012. Its large pop­u­la­tion and rel­a­tively pow­er­ful pro­duc­tion base give Indonesia the poten­tial to become an even more lucra­tive OTC, Pharma and Med­ical Device mar­ket in the future.

Indone­sia has a strong generic drugs sec­tor that accounts for 80% of the entire Rx mar­ket, of which Rx and OTC prod­ucts make up 70% and 30%, respec­tively. In recent years, the OTC seg­ment has exhib­ited a steady growth, attribut­ed to the increas­ing amount of self-medication and acces­si­bil­ity to more affordable drugs. Add in the sheer size of its pop­u­la­tion, and you know: Indone­sia sim­ply cannot be dis­missed.

    Indone­sia has a strong generic drugs sec­tor that accounts for 80% of the entire Rx mar­ket, of which Rx and OTC prod­ucts make up 70% and 30%, respec­tively. In recent years, the OTC seg­ment has exhib­ited a steady growth, attribut­ed to the increas­ing amount of self-medication and acces­si­bil­ity to more affordable drugs. Add in the sheer size of its pop­u­la­tion, and you know:
    Indone­sia sim­ply cannot be dis­missed.

    Of the 200-300 drug com­pa­nies that oper­ate in the Indone­sian mar­ket, approx­i­mately 40 are foreign-owned, and there are numer­ous food sup­ple­ment, cos­metic and med­ical rem­edy play­ers. Of the over­all phar­ma­ceu­ti­cal mar­ket in Indone­sia, for­eign drug-mak­ers con­sti­tute around 30%. Despite con­cerns about coun­ter­feit­ing and the low efficacy of generic prod­ucts, the IP pro­tec­tion and GMP man­u­fac­tur­ing stan­dards in Indone­sia are improv­ing with effective national reg­u­la­tions, for­eign invest­ments and joint ventures with multi-national com­pa­nies. A lim­ited num­ber of for­eign chain phar­ma­cies can be found in most major cities in Indonesia; these include Guardian, Wat­sons and Cen­tury Healthcare. There are also many pri­vately owned local phar­ma­cies (apotik). One of the bet­ter privately owned chains is Apotik Melawai, which is based in Jakarta.

    The National Agency of Drug and Food Con­trol (NA-DFC) is respon­si­ble for the reg­u­la­tion of phar­ma­ceu­ti­cal prod­ucts and drugs in Indone­sia. The pri­mary duties of the NA-DFC include pre-market eval­u­a­tions, leg­is­la­tion, reg­u­la­tion, stan­dard­isa­tion and GMP certification of med­ical prod­ucts.

    A drug reg­is­tra­tion appli­ca­tion can only be under­taken by phar­ma­ceu­ti­cal com­pa­nies located in Indone­sia, and this must go through a pre-registration process, which can take up to 40 work­ing days. This process involves a con­sul­ta­tion on the com­ple­tion of a reg­is­tra­tion dossier, as well as paying doc­u­ment and reg­is­tra­tion fees. Companies based out­side Indone­sia need to find a good local part­ner they can trust to con­duct the reg­is­tra­tion process on their behalf.